Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus - Report - MDSpire

Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus

  • By

  • Tingting Li

  • Hongliang Cong

  • Lin Wang

  • Wei Ruo

  • Wenyu Li

  • June 2, 2026

  • 0 min

Share

Clinical Report: Prognostic Significance of Lipoprotein(a) and Inflammatory-Lipid Index

Overview

This study evaluates the prognostic value of lipoprotein(a) and a novel Inflammatory-Lipid Index in patients with acute coronary syndrome and type 2 diabetes mellitus.

Background

Acute coronary syndrome (ACS) significantly contributes to cardiovascular mortality, particularly in patients with type 2 diabetes mellitus (T2DM), who face a higher risk of recurrent major adverse cardiovascular events (MACE). Despite advancements in lipid-lowering therapies, residual cardiovascular risk persists, necessitating the identification of non-traditional biomarkers.

Data Highlights

ParameterValue
MACE incidence in dual-high group57.7%
HR for dual-high vs dual-low8.01 (95% CI: 4.41–14.56)
C-statistic improvement0.741
NRI0.569
IDI0.053

Key Findings

  • Lipoprotein(a) and the Inflammatory-Lipid Index are independent predictors of MACE in ACS patients with T2DM.
  • Patients with high levels of both biomarkers had an 8-fold higher risk of MACE compared to those with low levels.
  • Non-linear correlations were observed between both biomarkers and MACE risk.
  • The dual-biomarker approach identifies a high-risk phenotype among ACS patients with T2DM.

Clinical Implications

The findings suggest that measuring lipoprotein(a) and the Inflammatory-Lipid Index can enhance cardiovascular risk assessment in ACS patients with T2DM. This dual approach may guide more tailored secondary prevention strategies for high-risk individuals.

Conclusion

The concomitant elevation of lipoprotein(a) and the Inflammatory-Lipid Index provides valuable prognostic information, identifying patients at particularly high risk for adverse cardiovascular events.

Related Resources & Content

  1. Frontiers in Endocrinology, 2026 -- Atherogenic index of plasma and the severity of coronary artery stenosis in patients with type 2 diabetes mellitus: a retrospective cross-sectional study
  2. European Journal of Preventive Cardiology, 2023 -- Association of Conventional Risk Factors, Ideal Cardiovascular Health, and Increased Lipoprotein(a) Levels
  3. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol, 2026
  4. Frontiers in Endocrinology — Quantifying the metabolic-inflammatory axis: synergistic value of TyG index and FAI in assessing CAD risk among MAFLD patients
  5. European Journal of Preventive Cardiology — The Risk of Atherosclerotic Cardiovascular Disease Linked to Lipoprotein(a) Remains Unaffected by C-Reactive Protein Levels
  6. 2025 ESC/EAS Dyslipidaemia Focused Update
  7. ACC/AHA Issue Updated Guideline for Managing Lipids, Cholesterol - American College of Cardiology
  8. Prognostic value of elevated lipoprotein (a) in patients with acute coronary syndromes: a systematic review and meta-analysis - PMC
  9. PROGNOSTIC VALUE OF HIGH-SENSITIVITY C-REACTIVE PROTEIN (HS-CRP) IN PREDICTING FUTURE CARDIOVASCULAR EVENTS: A SYSTEMATIC REVIEW AND META-ANALYSIS - ScienceDirect
  10. Full article: High apoB/apoA-1 ratio is a strong risk predictor of major adverse cardio- and cerebrovascular events part 1: a review basis for updating guidelines
  11. Content Click below to navigate through the docu
  12. Design and Rationale of Lp(a)HORIZON Trial: Assessing the Effect of Lipoprotein(a) Lowering With Pelacarsen on Major Cardiovascular Events in Patients With CVD and Elevated Lp(a) - ScienceDirect
  13. Lepodisiran — A Long-Duration Small Interfering RNA Targeting Lipoprotein(a) | New England Journal of Medicine

Original Source(s)

Combined prognostic value of lipoprotein(a) and an integrated inflammatory-lipid index in patients with acute coronary syndrome and type 2 diabetes mellitus

  • by Tingting Li, Hongliang Cong, Lin Wang, Wei Ruo, Wenyu Li

  • June 2, 2026

Related Content

Tenecteplase Fails to Boost EVT Outcomes

Phase 3 stroke trial leaves open the possibility of clinically meaningful benefit or harm in selected late-window patients.

Diabetic Retinal Disease Rates Narrow by Diabetes Type

US claims data showed rising prevalence of diabetic retinal disease in type 1 and type 2 diabetes, while incidence declined in type 1 diabetes and moved closer to type 2 rates by 2022.

Electroacupuncture alleviates myocardial ischemia-reperfusion injury by targeting and inhibiting NLRP3 inflammasome-mediated cardiomyocyte pyroptosis via serum exosomal miR-22-3p